Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol Combined With Novel Endocrine Therapy and ADT for Neoadjuvant Treatment in High-Risk Prostate Cancer
NCT07311915Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of propranolol in prostate cancer (PCa), sponsored by Zhongda Hospital, Southeast University. Primary endpoints: Pathological Complete Response at 12 weeks and Minimal Residual Disease at 12 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
propranolol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07311915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311915.